Digital Transformation Opportunities Corp.

First-quarter 2024 revenue was $364.3 million, up from $303.7 million in the year-ago period, an increase of $60.6 million or 20%. Revenue growth came mainly from a 12.8% increase in revenue per encounter and a 6.2% increase in patient encounters. Cost of revenue was $354.9 million versus $278.5 million last year, with higher drug and medical supply costs and increased cost per encounter weighing on margins; cost of revenue also included $13.3 million of equity-based compensation. Net loss before non-controlling interest was $24.9 million, compared with a net loss of $1.5 million in Q1 2023, and adjusted EBITDA was $2 million versus $4 million a year ago. At quarter-end, total liquidity was $132.7 million, including $74.9 million of cash and cash equivalents, $30.1 million of short-term marketable securities, and borrowing capacity under the PNC facility and line of credit. The company did not provide formal next-quarter or full-year financial guidance on this call.

Todd Schonherz said momentum from the prior year carried into 2024 and emphasized execution on growth and strategic priorities. He pointed to two completed acquisitions in the quarter, two more announced in Q2, expansion into Texas, Maryland, Hawaii, and Georgia, and the addition of 17 providers in Q1 and 40 year-to-date. He framed AON’s model as differentiated by operational autonomy, scale, integrated pharmacy and lab, centralized back office, and aligned incentives, and sounded optimistic about MiBA and NOVA as new technology-driven enhancements.

David Gould focused on the quarter’s financial bridge: revenue up 20% to $364.3 million, driven by pricing and volume, but cost of revenue rising to $354.9 million due to higher drug and supply costs, higher cost per encounter, and $13.3 million of equity-based compensation. He noted net loss before non-controlling interest widened to $24.9 million and adjusted EBITDA declined to $2 million. On liquidity, he cited $132.7 million total liquidity, including $74.9 million in cash and equivalents, $30.1 million in short-term marketable securities, $26.7 million of incremental borrowing capacity under the PNC loan facility, and $1 million under the PNC line of credit; $81.3 million was outstanding on the PNC loan at 7.1%, while the line of credit was undrawn.

There was no substantive analyst Q&A in the transcript, so no specific questions about margins, acquisitions, or capital allocation were addressed on the record. The closest discussion points were management’s commentary on integration of newly acquired practices, the launch of MiBA and NOVA, and the departure of CFO David Gould, with Dave Afshar set to become interim CFO. Management did not give formal guidance, so investors were left to infer direction from the quarter’s operating momentum and cost pressures.